Japanese drugmaker Teijin Pharma (TYO: 3401) has bought the rights to develop and commercialize somavaratan (VRS-317), a potential long-acting form of recombinant growth hormone (rhGH), in Japan.
Teijin has paid USA-based Versartis (Nasdaq: VSAR), an endocrine-focused biopharma which is developing somavaratan for the treatment of growth hormone deficiency (GHD), $40 million in an upfront payment and could pay $100 million more in potential development, regulatory and sales milestones.
It estimates the market size of the existing growth hormone products in Japan for pediatric GHD at $580 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze